Pfizer Inc. presented the results of preclinical hemophilia treatment-related studies at the World Federation of Hemophilia (WFH) 2010 Congress in Buenos Aires, Argentina, in July.
Pfizer reported that preclinical studies in mice suggest that there is a potential use for recombinant factor Xa to ensure adequate clotting in hemophilia patients, bypassing existing deficiencies in other factors, such as factor VIII or IX. Other preclinical studies showed that an enhanced recombinant factor VIIa molecule might effectively treat bleeding while decreasing inhibitor rates.
“We are very excited to present these data, which highlights the strength of our pipeline and our enduring commitment to provide recombinant products for the hemophilia community,” said Brenda Cooperstone, MD, vice president of clinical development and medical affairs for the Specialty Care Business Unit at Pfizer. “Our investigation of novel therapies for hemophilia treatment remains ongoing and we will continue to work closely with our partners—including the World Federation of Hemophilia—to help improve hemophilia care worldwide.”
Source: EurekAlert, July 9, 2010
